Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 7/20 | 0.47 |
| ▸ | FGF1 | P05230 | 2/20 | 0.38 |
| ▸ | FGF2 | P09038 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | IGF2R | P11717 | 1/20 | 0.37 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.37 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375702 | 1.00 | LGALS8 (0.47) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL19499655 | 0.95 | LGALS8 (0.51) | LGALS8PTPN1LGALS9LGALS1LGALS3 | |
| SCHEMBL29378663 | 0.95 | LGALS8 (0.51) | LGALS8PTPN1LGALS9LGALS1LGALS3 | |
| SCHEMBL24495028 | 0.93 | LGALS8 (0.48) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL24495271 | 0.91 | LGALS8 (0.48) | LGALS8PTPN1LGALS9LGALS1LGALS3 | |
| SCHEMBL29379207 | 0.87 | LGALS8 (0.45) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL24495058 | 0.87 | LGALS8 (0.45) | LGALS8PTPN1LGALS9LGALS1LGALS3 | |
| SCHEMBL29376308 | 0.86 | AMY1A (0.39) | LGALS8FGF1IGF2RLGALS9LGALS1 | |
| SCHEMBL19499653 | 0.86 | AMY1A (0.39) | LGALS8FGF1IGF2RLGALS9LGALS1 | |
| SCHEMBL24494995 | 0.86 | LGALS8 (0.44) | LGALS8PTPN1LGALS9LGALS1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177507-A1 | NOVEL COMPOUND AND USE OF SAME | NAGASE & CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-10202627-B2 | Method for producing trehangelin | THE KITASATO INSTITUTE (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20170306371-A1 | METHOD FOR PRODUCING TREHANGELIN | NAGASE & CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170306371-A1 | METHOD FOR PRODUCING TREHANGELIN | NAGASE & CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177507-A1 | NOVEL COMPOUND AND USE OF SAME | TXNRD2, GPX4, GPX1 | LGALS8 3562/4885FGF1 4105/4885FGF2 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.